The Valley Desk

NCT06136650 · Interventional trial

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Overall registry status Recruiting

Phase 3

Conditions Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov